Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
The Pharma Letter
Look back at pharma news to Aug 10
"MyoKardia’s success in a Phase II hypertrophic cardiomyopathy trial is likely spurring investor speculation that the group could be a target for its partner and investor…
Seeking Alpha
Snippet Roundup: A Small Success For Galapagos And A Big One For Karius
"Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items."
Seeking Alpha
Rebiotix Tries To Get One Up Over Seres
"We're building on three successful phase IIs... they've had one phase II programme that failed, and they have no other ones. What they're choosing to do is really…
MedCity News
In an era of mega-rounds, Roivant Sciences still makes a splash with $1.1B haul
"Two new reports by Evaluate Ltd’s news and analysis arm, EP Vantage, highlight the wider trend."
Seeking Alpha
Looking Beyond Factors In Hemophilia
"EP Vantage - Newsletter provider, biotech, healthcare"
Seeking Alpha
Does Roche Have The Hemophilia X Factor?
"I think [Roche's (OTCQX:RHHBY) emicizumab has been shown to be that," Guy Young of the Children's Hospital Los Angeles tells EP Vantage."
Seeking Alpha
Redx's Strange Insolvency Triggers Imbruvica Follow-On Buzz
"When the recently listed UK biotech's chief executive spoke to EP Vantage two years ago the focus was cancer and Imbruvica-resistant patients"
MedCity News
It’s not a competition but… Kite’s CAR-T therapy just claimed a first in Europe
"According to E.P. Vantage’s Jacob Plieth, the El Segundo facility would also service Europe."
PharmExec
Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?
As ICER noted in its May whitepaper, worldwide revenues from orphan drugs topped $100 billion in 2015, and could double over the next five years, according to…
